TP53 and prostate carcinoma: A number of frequent genomic changes are shared by primary and metastatic prostate cancer, including E26 transformation-specific (ETS) fusions, point mutations in SPOP, FOXA1, and TP53, and copy number alterations involving MYC, RB1, and PTEN, although these alterations are differentially enriched at different stages of prostate cancer12,13.